ARGX
NASDAQ
$846.19
Argen X SE (ARGX)
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $1,055.13 (+24.69%)
Market Cap
$57B
PEG Ratio
0.21
Revenue 5Y CAGR
+98.17%
Profit Margin
28.2%
Price Chart
Valuation
Market Cap$57B
P/E24.30
Forward P/E32.89
PEG0.21
P/S11.27
P/B7.33
Profitability
Total Revenue (TTM)$7.73B
Gross Profit (TTM)$3.24B
EBITDA$1.13B
Profit Margin28.2%
Operating Margin30.4%
EPS$35.51
Financial Health
Debt-to-Equity1.1%
Free Cash Flow Yield1.73%
Growth & Risk
Revenue 5Y CAGR+98.17%
Beta (5Y)0.46
Sharpe Ratio1.29